Member Info for Hartlebury

The article I read quoted MP Young saying that “he believed they would be 30 minute spit tests”

The only saliva test (lateral flow) I see on government site is Biosensor’s? https://www.gov.uk/government/publications/assessment-and-procurement-of-coronavirus-covid-19-tests/lateral-flow-devices-results

“...MP said he believed that the tests would be 30 minute spit tests” does Novacyt have that test?

Porky it would be a judgement call involving the company’s nominated adviser (and pushed by the AIM team at the stock exchange if it looked very obvious and nothing had been confirmed or denied). At present this isn’t really a rumour but simply speculation, Novacyt is a pretty obvious target for the big pharma’s. And the share price, although volatile, hasn’t reacted in such an extreme manner as to be linked to a rumour. These are the indicators that might prompt an rns.

Let’s just say we had quite different experiences!

Very exciting on the way up...exciting certainly wasn’t the appropriate word yesterday!

I don’t think this has been linked yet but well worth a watch

https://www.youtube.com/watch?v=7T4J7hmNDgg

I hope I can post links by now... https://twitter.com/rick_shares/status/1321767561315364864?s=21

Donotrader ‘Not a good indicator’ - do you mean the French opening price doesn’t help indicate where the market in the uk will go or that it’s low and therefore a bad sign?

Hi Wilson I would love this to be true but (and I say this believing that there’s nothing already in the public domain about it)if it was then under the AIM rules, NCYT would have to release an RNS announcing it and I’m sure they would be keen to do so.

On breath tests, along with 80% accuracy wasn’t the cost £75 a test? When Novacyt’s are apparently $10 with much higher accuracy? I’m not saying breath tests won’t be a threat in the relatively near future but there’s clearly some work and further trials (98 in the test documented people isn’t many) to be done yet. And still the fact remains that it’s unlikely that any single product can be produced in the volumes necessary to satisfy the enormous demand that appears to be inevitable if life is to return to any kind of normality.

Thought this AIM rule might be useful...

“15. General Disclosure of Price Sensitive Information

An AIM company must issue notification without delay of any new developments which are not public knowledge, which, if made public, would be likely to lead to a significant movement in the share price of its AIM securities. By way of example, this may include matters concerning a change in:
-its financial condition
- its sphere of activity
- the performance of its business; or
- its expectations of its performance.

As with other AIM rules, there is room for interpretation here but if I would suggest that either winning stage 2 of NHS contract/care homes or NOT doing so would be likely to move the share price and neither, obviously is in the public domain. So for me right now, as much as I’d love to see a good rns, no news is also good news!

The ODX rns is interesting and obviously takes them out of the running in guessing who is cornering the testing market. The sharp rise in Pillar 1 testing capacity yesterday was remarked upon here - this morning I also read about Belgium and the Czech Republic having similar significant increases in testing. Someone must be supplying the tests and you’d expect them to be shouting about it. Also, an rns isn’t always good news (see ODX)..the company must release one if current expectations of performance are materially different from the market’s information. All the news so far from NCYT is good, we know for sure that the Primerdesign tests are going into hospitals here. Don’t underestimate the painful bureaucracy of getting contracts through the government system, even in a pandemic. I suspect that there are a lot of t’s being crossed and i’s dotted, the last thing Boris wants is a repeat of the out of date PPE purchases and £millions wasted on inadequate tests. They have to make sure they get this one right!

Novice have you watched the discussion last week with Richard and Andy Brough? Richard said that Novacyt came to him looking for help back in December as the company was on the verge of bankruptcy. He was very impressed with the company and management team but a placing at a discount was made impossible by Nova’s French listing. So they were there in December, developing cutting edge diagnostic testing...also apparently had contacts in China who gave them the heads up on COVID-19 heading this way and acted on it. Combination of good products, good timing and then front of the pack when the government was looking for ways to improve testing...

Just reading that ministers are discouraging people from using the private Boots tests - results do not feed through to government data and also there are concerns over accuracy...

“However, concerns have been raised about the accuracy of the test in a non-clinical setting. Julian Tang, professor in respiratory sciences and a clinical virologist at the University of Leicester, said: “These types of rapid antigen tests have been used for years for other respiratory viruses like influenza and RSV — and are of variable sensitivity.

“They perform better on samples with high viral loads — such as those taken early in infection, and in children who usually shed more of those viruses

“Generally better results are obtained when such kits are assessed by laboratory-trained personnel, as is usually the case when generating these product specifications.”

Pete7 - huge tip in answer to your question ‘why the massive price predictions for Novacyt’... read just a tenth of the research generously linked on this board and you will begin to see why! There’s a basis for belief in the company that goes beyond the share price being lower than another company’s that isn’t remotely comparable. There’s an element of gambling in this for all of us but you appear to be taking it to a stupendous level if you don’t understand the first thing about SP vs MC and fundamentals of different businesses.

ShaunP I will mention it. To be clear, no stock tips were being given...he was suggesting lse as a whole rather than specific boards. As far as I am aware he isn’t invested in NCYT.

Also ShaunP..did you catch AB’s mention of EKF in the discussion? He sort of got interrupted just at that point though..

To be fair, the guy who saw Novacyt in December liked the company (especially management team) a lot but they couldn’t help them with the placing because the listing in France prevented them from undertaking one at a discount. I got the impression that it then fell off his radar until he started looking at private covid tests for travel.

With regard to Andy Brough’s mention of great research being found on bulletin boards, he is a friend and I can confirm he is a fan of lse, it was him who sent me here!

As far as ‘Test, Track and Trace’ goes, the wheels appear to be very much falling off...(apologies, I can’t post links as not here long enough yet) but the Irish Times is reporting that around 2,500 Individuals who tested positive over the weekend are being asked to undertake their own contact tracing...Testing becoming the crux of everything (followed closely by people isolating as they should).